Get the Stockscreener App
0.9441
1.82%
0.0169
Biocardia Inc stock is traded at $0.9441, with a volume of 230.38K.
It is up +1.82% in the last 24 hours and down -23.25% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$0.9272
Open:
$0.94
24h Volume:
230.38K
Relative Volume:
1.85
Market Cap:
$14.29M
Revenue:
$3,000
Net Income/Loss:
$-7.78M
P/E Ratio:
-0.9125
EPS:
-1.0346
Net Cash Flow:
$-7.49M
1W Performance:
-10.94%
1M Performance:
-23.25%
6M Performance:
-20.67%
1Y Performance:
-39.48%
1-Day Range:
$0.87
$0.9699
1-Week Range:
$0.9093
$1.08
52-Week Range:
$0.75
$1.80
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCDA
Biocardia Inc
|
0.9441 | 14.29M | 3,000 | -7.78M | -7.49M | -1.0346 |
VRTX
Vertex Pharmaceuticals Inc
|
508.13 | 128.79B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
798.88 | 82.25B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.25 | 53.66B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting - GlobeNewswire Inc.
BioCardia president and CEO Peter Altman buys $1,030 in shares - Investing.com
At $1.03 a share, BioCardia (BCDA) CEO Peter Altman buys 1,000 shares. - Stock Titan
BioCardia CEO Peter Altman buys $1,995 in stock By Investing.com - Investing.com Canada
BioCardia CEO Peter Altman buys $1,995 in stock - Investing.com
BioCardia (BCDA) CEO buys shares at an average $1.05 each, bringing his direct holdings to 383,885. - Stock Titan
BioCardia Shares Fall 10% After Hours: Here's Why - Benzinga
BioCardia Shares Fall 10% After Hours: Here's Why - TradingView
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com India
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com UK
BioCardia to Present CardiAMP, Helix and Heart3D Progress at H.C. Wainwright Global Investment Conference - Quiver Quantitative
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
BioCardia to present CardiAMP regulatory progress, Helix and Heart3D updates at H.C. Wainwright - TradingView
A heart-failure cell therapy could reach Japanese regulators by year-end. BioCardia is preparing the filing. - Stock Titan
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys 800 shares for $872 - Bitget
BioCardia CEO Peter Altman buys $872 in company stock By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys $872 in company stock - Investing.com
BioCardia CEO Peter Altman buys $872 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman buys $872 in company stock - Investing.com
BioCardia (BCDA) CEO adds 800 shares in open-market buy - Stock Titan
BioCardia Inc. Warrant (BCDAW) Key Financial Ratios – Valuation, Profitability & More - Value Research
BioCardia (BCDA) Session: Finishes 4.95% Higher at $1.06 at the Close; Price Setup: Price Remains Between $1.01 Support and $1.11 Resistance on the DaySmart Beta Flow - vinanet.vn
BioCardia receives FDA confirmation on Helix catheter meeting By Investing.com - Investing.com Nigeria
BioCardia Advances Helix Catheter Toward De Novo Approval - TipRanks
BioCardia receives FDA confirmation on Helix catheter meeting By Investing.com - Investing.com India
BioCardia (BCDA) Session: Finishes 4.95% Higher at $1.06 at the Close; Price Setup: Price Remains Between $1.01 Support and $1.11 Resistance on the DayDonchian Channel - dars.gov.et
BioCardia Receives Nasdaq Notice on Minimum Bid Price - The Globe and Mail
BioCardia Received Notice of Noncompliance - TradingView
BioCardia’s Q2 2026 Update Keeps the Regulatory Story Alive, but Capital Still Drives the Risk - AlphaStreet
BioCardia CEO Peter Altman acquires 5,400 common shares worth $5,022 - Bitget
BioCardia CEO Peter Altman buys $5,022 in company stock - Investing.com
BioCardia CEO Peter Altman buys $5,022 in company stock - Investing.com
BioCardia (BCDA) CEO buys 5,400 shares in open market - Stock Titan
BCDA Q2 2026 Earnings: EPS Surprise of 29.19% Narrows Losses as Shares Climb 4.82%Estimate Revision Count - vinanet.vn
BioCardia (BCDA) Pushes Higher: Micro-Cap Biotech Gains 4.8% as It Nears $1.02 ResistanceIceberg Order - vinanet.vn
BioCardia (BCDA) Pushes Higher: Micro-Cap Biotech Gains 4.8% as It Nears $1.02 ResistanceValue Area High - dars.gov.et
BCDA Q2 2026 Earnings: Narrower-than-Expected Loss Drives Shares Up 4.82%Earnings Revision Upgrade - vinanet.vn
Why Did BCDA Stock Surge More Than 50% Today? - Stocktwits
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com Canada
BioCardia CEO Peter Altman buys $1,748 in company stock - Investing.com
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com India
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com UK
BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price - Stock Titan
BioCardia (BCDA) Holds at $0.88 as Range-Bound Trading PersistsTriple Top - vinanet.vn
BioCardia (BCDA) Drops 5.6% to $0.88 as Micro-Cap Biotech Tests Support LevelInsider Buying Alerts - vinanet.vn
BioCardia (BCDA) Advances Regulatory Pathway, Faces High Price-t - GuruFocus
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... - Yahoo! Finance Canada
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulat - GuruFocus
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Sep 23 '26 |
Buy |
1.05 |
1,900 |
1,995 |
383,885 |
| Altman Peter | President and CEO |
Sep 03 '26 |
Buy |
1.09 |
800 |
872 |
381,985 |
| Altman Peter | President and CEO |
Aug 17 '26 |
Buy |
0.93 |
5,400 |
5,022 |
381,115 |
| Altman Peter | President and CEO |
Aug 13 '26 |
Buy |
0.92 |
1,900 |
1,748 |
375,785 |
| Altman Peter | President and CEO |
Jul 29 '26 |
Buy |
0.78 |
5,000 |
3,900 |
373,885 |
| Altman Peter | President and CEO |
Jul 17 '26 |
Buy |
0.83 |
500 |
415 |
368,885 |
| Altman Peter | President and CEO |
Jul 15 '26 |
Buy |
0.86 |
1,500 |
1,290 |
368,385 |
| Altman Peter | President and CEO |
Jul 14 '26 |
Buy |
0.88 |
2,800 |
2,464 |
366,885 |
| Altman Peter | President and CEO |
Jul 10 '26 |
Buy |
0.94 |
1,000 |
940 |
369,485 |
| Altman Peter | President and CEO |
Jul 09 '26 |
Buy |
0.90 |
1,000 |
900 |
368,485 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):